NCT06557343Recruiting
Single-Cell Sequencing Analysis of Radiation Pneumonitis Signals In Patients Treated For Cancer With Radiotherapy
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
Patients with signs of radiation induced lung inflammation, who are referred for a clinical bronchoscopy for investigation, will have a sample sent for single cell sequencing. This is a novel technique which allows for identification of which cells are present and what they are doing. This hopes to better understand radiation pneumonitis, a dose-limiting toxicity in cancer treatment which can be highly morbid and even fatal.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5 (estimated)
- First submitted
- 3 Jun 2024
- Start date
- Oct 2024
- Primary completion date
- Oct 2026
- Lead sponsor
- NHS Lothian
- NCT number
- NCT06557343
What you commit to
- Study type: Observational
- Planned participants: 5
- From Oct 2024 to the primary completion date, Oct 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to bronchoscopy, ie. Previously not tolerated, unable to lie flat, Sp02 \<92% on air
Other illness
- Test positive for Covid-19 within the preceding six weeks to enrolment
Other
- Patient requires admission or oxygen dependant
Who the study is looking for
- Age over 18 years
- Patient has received thoracic radiotherapy and has clinical or radiological features in fitting with a diagnosis of Radiation Pneumonitis (onset one to four months post-RT with breathlessness, especially exertional, cough, chest discomfort, which is persistent over weeks, a chest x-ray \[CXR\] may demonstrate patchy or widespread opacification although can be normal.)
- Must be ambulant, oxygen independent with SpO2 \>92% on air and haemodynamically stable to be considered safe for a bronchoscopy.
- Willing to undergo and likely able to tolerate bronchoscopy, ie. Can lie flat without compromising ventilation, and able to consent to the ELFMAN Protocol and SPITFIRE trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Edinburgh Cancer Centre Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Recruiting |
| Henderson Lab Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Not yet recruiting |
| Centre for Information Research, University of Edinburgh Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.